February 22, 2007 -- Allergan paid $97 million for EndoArt, which produces remote-controlled implants for obesity and other conditions; Genentech fell under the double burden of two negative news stories; Advair from GlaxoSmithKline failed to meet its endpoint in a COPD trial; Hollis-Eden released positive data from pre-clinical tests of a prostate/breast cancer drug; Ikaria and INO Therapeutics were both absorbed into Ikaria Holdings in a deal worth $670 million; Emergent BioSolutions said the government cancelled its request for proposals to supply anthrax vaccines; GlaxoSmithKline has begun warning that rosiglitazone causes bone fractures in female patients; and Cell Genesys and Medarex reported encouraging results from immunotherapy GVAX. The Centient Biotech 200™ fell 31 points to 4054, a loss of .76%. More details...
